Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Scandinavian ChemoTech AB (publ)
  6. News
  7. Summary
    CMOTEC B   SE0009242654

SCANDINAVIAN CHEMOTECH AB (PUBL)

(CMOTEC B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Scandinavian ChemoTech publ : introduces a separate legal entity for its Animal Care business

07/07/2020 | 05:01am EDT

ChemoTech has today made the strategic decision to create a fully owned subsidiary for its Animal Care business.

The new entity will be a subsidiary fully owned by Scandinavian ChemoTech AB. The intention of creating a new entity, is to enable diversified strategies for the animal- and human care businesses respectively, while maintaining the synergies in technology and overhead administration.

"We believe this decision will have a strong impact on the two businesses as it will strengthen the focus for each business area. It will also allow for separate and focused tracks in the further development of strategies, partnerships and alliances to fully reach their anticipated potentials." - says Mohan Frick, CEO

For more information, please contact:

Mohan Frick, Co-Founder and CEO

Phone: +46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: ca@vhcorp.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Tuesday July 7th 2020 at 11.00 (CET).

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.

https://news.cision.com/chemotech/r/scandinavian-chemotech-introduces-a-separate-legal-entity-for-its-animal-care-business,c3150043

https://mb.cision.com/Main/14967/3150043/1275955.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about SCANDINAVIAN CHEMOTECH AB (PUBL)
04/30SCANDINAVIAN CHEMOTECH  : strengthens its working capital through loans of SEK 1..
AQ
04/30SCANDINAVIAN CHEMOTECH  : has received a date for a final revision of its CE mar..
AQ
04/30SCANDINAVIAN CHEMOTECH  : stärker rörelsekapitalet genom lån på 10 MSEK
AQ
03/16SCANDINAVIAN CHEMOTECH AB  : (publ) strengthening its position despite ongoing p..
AQ
02/03SCANDINAVIAN CHEMOTECH  : receives a final injunction from the European Patent O..
AQ
01/05SCANDINAVIAN CHEMOTECH  : enters into an agreement with Erik Penser Bank to moni..
AQ
2020SCANDINAVIAN CHEMOTECH AB  : receives final injunction on EU patent for its tech..
AQ
2020SCANDINAVIAN CHEMOTECH  : subsidiary, Vetiqure AB, has today received an order f..
AQ
2020SCANDINAVIAN CHEMOTECH  : has been invited to participate in two prestigious eve..
AQ
2020SCANDINAVIAN CHEMOTECH AB  : (publ) Interim report Q2 January - June 2020 Execut..
AQ
More news
Financials
Sales 2020 1,41 M 0,17 M 0,17 M
Net income 2020 -11,7 M -1,40 M -1,40 M
Net cash 2020 1,43 M 0,17 M 0,17 M
P/E ratio 2020 -5,72x
Yield 2020 -
Capitalization 117 M 14,1 M 14,1 M
EV / Sales 2019 10,2x
EV / Sales 2020 56,9x
Nbr of Employees 7
Free-Float 80,7%
Chart SCANDINAVIAN CHEMOTECH AB (PUBL)
Duration : Period :
Scandinavian ChemoTech AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Stefan Mohan Frick Chief Executive Officer & Director
Gerd Inga-Lill Forslund Larsson Chairman
Johan Wennerholm Independent Director
Klaus Gustav Göran Hellers Non-Independent Director
Sector and Competitors